Navigation Links
Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor
Date:4/4/2013

enior Medical Director of the MM-121 program at Merrimack. "We are disappointed by the overall clinical results in this population, but are encouraged by our preliminary biomarker analysis which we believe will be important for the identification of a predictive diagnostic when analyzed in the context of the overall clinical development program."

This is one cohort (Group C) of a larger, ongoing randomized Phase 2 study evaluating MM-121 to treat other groups of patients with NSCLC. The study also includes patients with EGFR wild-type tumors who have recurring or progressive disease following at least one chemotherapy-containing regimen in the metastatic setting and who have had no prior EGFR-TKI therapy (Group A) and patients with a known EGFR-activating mutation who have had no prior EGFR-TKI therapy in the metastatic setting (Group B). MM-121 is also being evaluated in Phase 2 studies for the treatment of advanced ovarian cancer, hormone-receptor positive breast cancer and HER2 negative breast cancer.

MM-121 is a fully human monoclonal antibody that targets ErbB3, a cell surface receptor implicated in tumor growth and survival. By inhibiting ErbB3 signaling, MM-121 is designed to restore sensitivity, delay resistance and enhance the anti-tumor effect of a combination therapy partner. Sanofi and Merrimack entered into an exclusive, global license and collaboration agreement for MM-121 in 2009.

About Merrimack Pharmaceuticals, Inc.                                                                        
Merrimack Pharmaceuticals is a biopharmaceutical company discover
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
2. Valeant Pharmaceuticals Provides Update to Recent Event
3. Oramed Pharmaceuticals Granted Japanese Patent for its Core Technology in Oral Delivery of Proteins
4. Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of $24.00 Per Share In Cash
5. European Nuclear Medicine / Radiopharmaceuticals Market Worth by Reach $1.6 Billion by 2017
6. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
7. Valeant Pharmaceuticals Announces Private Exchange Offer
8. Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
9. Inovio Pharmaceuticals to Present at BioCenturys "Future Leaders in the Biotech Industry" Conference
10. Convergence Pharmaceuticals Announces Successful Interim Data from Ground-Breaking Phase II Trigeminal Neuralgia Study
11. Pharmaceuticals - Scandinavia Industry Guide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... INDIANAPOLIS and LYON, France ... (NYSE: LLY ) and Adocia (Euronext Paris: ... focused on developing an ultra-rapid insulin, known as BioChaperone ... type 2 diabetes. BioChaperone Lispro relies on Adocia,s proprietary ... Lilly and Adocia will develop BioChaperone Lispro ...
(Date:12/17/2014)... 2014 Los beneficios y ganancias ... nivel de gasto en investigación y desarrollo   ... 30 de septiembre de 2014) ZEISS aumentó sus ingresos ... euros (año anterior: 4.190 millones de euros) a pesar ... (EBIT) crecieron un 14 por ciento, a 360 millones ...
(Date:12/17/2014)... 2014  Northstar Global Business Services, Inc. (OTCPink:MDIN) ... has made their final decision and has determined ... stock effective December 15, 2014, and has resumed ... and book entry transfer services. All deposit restrictions have ... again fully "DTC Eligible", and has resumed electronic ...
Breaking Medicine Technology:Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3ZEISS confirma su posición en un entorno difícil 2Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3
... Target Patients for ALIMTA(R), (pemetrexed for injection) ... Cancer, BARCELONA, Spain, Sept. 25 ... lung cancer (NSCLC) that,are classified as having ... when treated in the second-line setting with,ALIMTA(R) ...
... Mich. Sept. 24 Velcura Therapeutics, Inc., a,biotechnology ... the,U.S. Food and Drug Administration (FDA) Sept. 20 ... VEL-0230, a drug developed to treat bone,disease. The ... was to obtain feedback from the FDA,s Division ...
Cached Medicine Technology:Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes 2Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes 3Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes 4Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes 5Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes 6Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes 7Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes 8Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease 2Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease 3
(Date:12/19/2014)... B. E. Smith, the only full-service leadership ... retained to lead a national chief financial officer ... The top executive search firm in the healthcare industry, ... healthcare executives into organizations. , Johnson Memorial Hospital ... to the residents of Johnson County and the surrounding ...
(Date:12/19/2014)... If you have ever been unable ... probably wished you had an arsenal of treatments to ... and other breathing disorders. Currently, the only proven methods ... but other common treatments do exist. At the ... Antonio, TX, 34 asthma educators responded to a Harmonica ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Consilium ... at the AMSUS Society for Federal Health Professionals ... locum tenens industry to military and federal healthcare ... the National Veterans Small Business Engagement (NVSBE) conference ... continues to be a vital solution in addressing ...
(Date:12/19/2014)... Amy Norton HealthDay Reporter ... moms who were exposed to high levels of air pollution ... autism, a U.S. study suggests. Researchers found that of ... 2002, those exposed to the most air pollution during pregnancy ... developed autism. And exposure during the third trimester, specifically, showed ...
(Date:12/17/2014)... 2014 While countless companies tempt patients to ... the potential dangers of their purchase. Not only is the ... qualified doctor, but patients who buy hCG online are typically ... is actually no real hCG present. Illegal internet hCG is ... no safety standards and may contain unknown fillers that can ...
Breaking Medicine News(10 mins):Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 3Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 2Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 3Health News:Consilium Staffing Increasing Awareness of Locum Tenens through Conference Appearances 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 3Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 2Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 3
... More than eight out of 10 homeless people surveyed ... least one chronic health condition and more than half have ... they live in unsafe, unstable or unaffordable housing--had equally poor, ... The underlying cause for these health issues is poverty, said ...
... By Serena Gordon HealthDay Reporter , TUESDAY, ... as nuts, to your diet can lower your cholesterol more ... Foods with plant sterols also have known cholesterol-reducing properties, and ... cholesterol by more than 13 percent. A low-fat diet alone ...
... , New York, NY, August 24, 2011 Nearly three-quarters (72%) ... their jobs over the last two years said that they ... because of cost, according to a new Commonwealth Fund ... or medical debt, compared to about half (49%) who lost ...
... Aug. 23 (HealthDay News) -- Accidental exposure to highly ... the United States, a new study finds. Researchers ... in outpatient chemotherapy infusion centers and found that nearly ... exposed to the drugs. In the United States, ...
... , TUESDAY, Aug. 23 (HealthDay News) -- ... appears to worsen over time and may lead to an ... people with diastolic dysfunction, which often comes with advancing age, ... abnormal way and is accompanied by elevated filling pressures. ...
... August 23, 2011 In a joint research effort ... with help from scientists at The University of Pennsylvania, ... Health, investigators from the Florida campus of The Scripps ... allows cells to rid themselves of damaged mitochondria, which ...
Cached Medicine News:Health News:Study: 85 percent of homeless people have chronic health conditions 2Health News:Certain Foods Said to Help Lower Bad Cholesterol 2Health News:Certain Foods Said to Help Lower Bad Cholesterol 3Health News:Three quarters of those who have lost jobs and health insurance are skipping needed health care 2Health News:Three quarters of those who have lost jobs and health insurance are skipping needed health care 3Health News:Three quarters of those who have lost jobs and health insurance are skipping needed health care 4Health News:Nurses at Risk for Accidental Exposure to Chemo Drugs: Study 2Health News:Common Heart Dysfunction Can Help Bring on Heart Failure 2Health News:Scripps Research scientists define cellular pathway essential to removing damaged mitochondria 2
... The PROXIMATE Access 55 Articulating Linear ... blue cartridge or a thick-tissue green instrument ... forms a 55mm staple line., ,Benefits ... deeper access in narrow male pelvis. , ...
... The PROXIMATE Reloadable Linear Staplers deliver two staggered ... 90mm sizes. They may be reloaded up to ... TLH models fire heavy wire staples for thick ... are not interchangeable., ,Benefits include: , Parallel ...
... Loading Units With Titanium Staples ... TA™ (Single Use Reloadable Stapler ... Auto Suture™ PREMIUM MULTIFIRE TA™ ... gynecological, pediatric and thoracic surgical ...
Single Use Reloadable Stapler with Titanium Staples., ,The Auto Suture™ PREMIUM MULTIFIRE TA™ stapler has applications in abdominal, gynecological, pediatric and thoracic surgical proced...
Medicine Products: